About
Molecular Diagnostics: Celiac & Bowel
Glycominds International, an innovative diagnostics company, develops and commercializes gastrointestinal disease management tools and services. Glycominds' GI dry serum testing allow physicians to help identify patients who have Celiac Disease and Inflammatory Bowel Diseases (mainly Crohns Disease and Ulcerative Colitis) to achieve early, non-invasive, accurate and cost-effective diagnosis, predict Crohns Disease patients at a higher risk for more complicated disease, as well as monitoring Anti-TNF therapy. Glycominds was acquired by Medivie Therapeutic in 2014, expanding its product line.
Identity
| Name | Glycominds |
|---|---|
| Slug | glycominds |
| Type / kind | startup |
| Crunchbase ID | glycominds |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAoLHShYAJDA |
Status
| Status | inactive |
|---|---|
| Status reason | Acquired (Inactive) by Medivie Therapeutic on Apr 2014 - closed due to acquisition |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Modi'in-Maccabim-Re'ut |
| HQ address | HaShdera HaMerkazit, Modi'in-Maccabim-Re'ut, Israel |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesDigital HealthcareDigital Medical Diagnostics
Technologies
Materials & SubstancesNanomaterials
Target customers
Healthcare & Life SciencesHealthcareLaboratoriesMedical Devices IndustryMedical Equipment
Business models
B2B
Tags
chronic-deseasescrohn-s-diseasepharmaceuticalsceliac-diseaseautoimmune-diseases
Funding
| Total raised | — |
|---|---|
| Current stage | Acquired |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}